摘要
侵袭性真菌感染的增加导致抗真菌药物使用频率增高,真菌耐药性的出现成为不可避免的问题。在现有抗真菌药物有限且不良反应明显的情况下,美国食品药品监督管理局批准新型抗真菌药物艾瑞芬净上市,该药是天然产物英夫马芬净的化学半合成衍生物,具有广谱抗菌活性,对包括耐棘白菌素类、耐唑类药物在内的念珠菌和曲霉均具有较强的抗菌活性,目前临床多用于治疗外阴阴道念珠菌病。艾瑞芬净具有良好的口服生物利用度及耐受性,且不良反应少,是一种具有全新结构的β-1,3-葡聚糖合成酶抑制剂,在侵袭性真菌病感染的临床治疗中具有良好应用前景。该文主要对艾瑞芬净的研发过程、临床研究及药物相互作用等方面进行综述。
With the increase of invasive fungal infections,the use of antifungal drug has become more frequently,and the emergence of fungal resistance has become an inevitable problem.Given the limited availability of existing antifungal drugs and their severe side effects,the United States Food and Drug Administration has approved a new antifungal drug,ibrexafungerp,which is a semi-synthetic chemical derivative of the natural product enfumafungin.It has broad-spectrum antibacterial activity,demonstrates strong antibacterial activity against Candida and Aspergillus,including those echinocandins-and azoles-resistant strains.It's currently used in the clinical treatment of vulvovaginal candidiasis.Ibrexafungerp has good oral bioavailability and tolerance,with few adverse reactions.It is a β-1,3-glucan synthase inhibitor with a new structure and has a good prospect in the clinical treatment of invasive fungal infections.This article reviewed the research and development process,clinical research and drug interactions of ibrexafungerp.
作者
汪君怡
陈浩东
汤佳伟
杨松柏
陈少欣
WANG Junyi;CHEN Haodong;TANG Jiawei;YANG Songbai;CHEN Shaoxin(China state Institute of Pharmaceutical Industry,Shanghai Institute of Pharmaceutical Industry,National Key Laboratory of Lead Druggability Research,Shanghai 201203,China)
出处
《世界临床药物》
2025年第9期972-977,共6页
World Clinical Drug
基金
科技部国家重点研发计划“绿色生物制造”项目(2021YFC2102100)
上海启明星培育(扬帆专项)项目(23YF1445800)。
